甘麦大枣汤改善肿瘤抑郁的临床疗效

目的：观察甘麦大枣汤治疗肿瘤抑郁的临床疗效。方法：选取2018年1月至2018年10月上海中医药大学附属龙华医院收治的肿瘤抑郁患者72例作为研究对象，按照随机数字表法分为对照组和观察组，每组36例。2组均给予抗肿瘤中成药消癌平片，观察组加用甘麦大枣汤。2组疗程均为28 d，比较2组治疗前后抑郁自评量表（SDS）评分，抑郁相关指标5-羟色胺(5-HT)，同型半胱氨酸(Hcy),肿瘤坏死因子-α(TNF-α)，白细胞介素-6(IL-6)、自然杀伤细胞(NK)、免疫学指标(CD3+、CD4+、CD8+、CD4+/CD8+)水平及生命质量评分(QLQ-C30)的变化情况。结果：治疗后，SDS评分观察组明显低于对照组，差异有统计学意义(P<0.05)。抑郁相关炎性反应递质指标5-HT、TNF-α、IL-6改善，观察组好转程度明显高于对照组，差异有统计学意义(P<0.05)。免疫学指标CD3+、CD4+、CD4+/CD8+水平观察组改善程度明显高于对照组，差异有统计学意义(P<0.05)。生命质量量表中躯体、角色、情绪、社会功能、总健康状况、疲倦、失眠项目评分差异有统计学意义(P<0.05)。结论：甘麦大枣汤联合消癌平片治疗肿瘤抑郁患者，可明显减轻抑郁，提高机体免疫功能，改善生命质量。     

lncRNA ABHD11-AS1通过调控STAT1/STAT3表达促进非小细胞肺癌细胞增殖与迁移

  目的   探讨lncRNA ABHD11-AS1在非小细胞肺癌中的生物学功能和作用机制。  方法   选取2016年7月至2018年12月在广东医科大学附属医院行非小细胞肺癌手术的248例患者，采用χ2检验分析lncRNA ABHD11-AS1的表达与患者年龄、性别、临床病理分期、病理类型及吸烟状态的关系；采用Kaplan-Meier法分析ABHD11-AS1对非小细胞肺癌患者的预后意义；应用qRTPCR方法检测ABHD11-AS1在非小细胞肺癌组织和细胞系中的表达；通过体外功能测定评估敲低ABHD11-AS1对细胞增殖和转移的影响；通过Western blot实验探讨ABHD11-AS1在非小细胞肺癌中致癌作用的分子机制。  结果   lncRNA ABHD11-AS1高表达组较低表达组吸烟患者较少（P=0.02），分期更晚（P < 0.01）；ABHD11-AS1高表达预示非小细胞肺癌患者预后不良；ABHD11-AS1在非小细胞肺癌组织和癌细胞株中高表达；敲低ABHD11-AS1的表达可抑制体外细胞增殖和迁移；敲低ABHD11-AS1表达抑制STAT1和STAT3癌蛋白的表达。  结论   ABHD11-AS1可能通过促进STAT1和STAT3癌蛋白的表达，从而增加非小细胞肺癌细胞的增殖、集落形成以及迁移和侵袭能力。      

酪氨酸激酶受体RON与E-cadherin在子宫内膜异位症上的表达及意义

目的探讨酪氨酸激酶受体RON及上皮型钙粘蛋白(E-cadherin)在子宫内膜异位症(endometriosis,EMs)上的表达及意义。方法选择2017年7~12月深圳市龙岗区人民医院收治的42例EMs患者,术中分别留取新鲜异位内膜组织和在位内膜组织,随机选取子宫切除或诊断性刮宫治疗的非EMs患者42例,术中留取其正常子宫内膜组织。采用逆转录聚合酶链反应(RT-PCR)检测子宫内膜组织中RON mRNA的表达,采用免疫组织化学方法检测对应42例石蜡组织中RON蛋白和E-cadherin的表达,并分析RON蛋白和E-cadherin的相关性。结果EMs异位内膜组织RON mRNA及RON蛋白阳性表达率显著高于在位内膜组织及正常子宫内膜组织(P<0.001),在位内膜组织及正常内膜组织中E-cadherin阳性表达率显著高于异位内膜组织(P<0.001),且异位内膜组织中RON mRNA及RON蛋白的表达与临床分期有关(P<0.001)。在同一标本中RON蛋白和E-cadherin表达呈负相关关系(r=-0.497,P<0.05)。结论RON的过度表达与EMs的发生发展密切相关,联合检测RON和E-cadherin的异常对判断EMs的发生发展有一定的参考价值,RON可能成为诊断治疗EMs的新靶点。     

The Prognostic Role of Peritumoral Edema in Patients with Newly Diagnosed Glioblastoma: A Retrospective Analysis

ObjectivePrevious studies on glioblastomas (GBMs) have not reached a consensus on peritumoral edema (PTE)’s influence on survival. This study evaluated the PTE index’s prognostic role in newly diagnosed GBMs using a well-designed method.MethodsSelected patients were reviewed after a rigorous screening process. Their general information was obtained from electronic medical records. The imaging metrics (MTD, TTM, TTE) representing tumor diameter, laterality, and PTE extent were obtained by manual measurement in Syngo FastView software. The PTE index was a ratio of TTE to MTD. Multiple variables were evaluated using analysis of variance and Cox regression model.ResultsOf 143 patients, 62 were included in this study. MGMT promoter methylation and tumor laterality were both independent prognostic factors (p = 0.020, 0.042; HR = 0.272, 2.630). The lateral tumors’ index was higher than that of the medial tumors (57.7% vs. 42.6%, p = 0.027). Low-index tumors were located in relatively medial positions compared with high-index tumors (TTM, 4.9 vs. 12.8, p = 0.032). This finding indicated that the PTE index tended to increase with tumor laterality. Moreover, the patients with low-index tumors had a significant survival disadvantage in the univariate analysis but not in the multivariate analysis (p = 0.023, 0.220). However, further analysis found that the combination of tumor laterality and PTE statistically stratified the survival outcome. The patients with lateral high-index tumors survived significantly longer (p = 0.022, HR = 1.927).ConclusionsIn contrast with the previous studies, this study recommends combining PTE and tumor laterality for survival stratification in newly diagnosed GBMs.     

Clinical observation on the effect of Chinese medicine-“TCM formula” intervention on recurrence and metastasis of triple negative breast cancer

ObjectiveThis study used a prospective cohort study to observe the effect of triple-negative breast cancer on the 2-year disease-free survival rate with or without “TCM formula”.MethodsFrom November 1 st, 2016, the first patient was enrolled in the cohort study. A total of 356 patients were enrolled on January 30, 2019. Among them, 154 cases were followed up for 2 years. During the follow-up, there were 6 cases of shedding, so 6 cases were affected. A total of 148 cases were included in the analysis, including 73 in the exposed group and 75 in the non-exposed group. The exposed group was given “TCM formula” on the basis of standardized treatment, and the non-exposed group was treated with simple triple-negative breast cancer. The two groups visited each of the three months. The interview included safety examination (hematology and imaging). The endpoint was the difference in 2-year invasive disease-free survival between the exposed and non-exposed groups and the safety of the “TCM formula”.ResultsThere were 6 cases of shedding during the experiment and the shedding rate was 3.9 %. The 2-year rate of invasive disease-free survival in the exposed team was 88.7 % and the non-exposed group was 82.5 %. Logistic multivariate regression analysis predicted that “TCM formula” could reduce the disease-related recurrence and metastasis rate by 11 % (OR = 0.89, 95 % CI 0.37−0.956, P＜0.05). Through K–M survival analysis, TNBC patients with age ≤35 years and regional lymph node stage N1 may be the benefit group of “TCM formula”(P＜0.05). During the study, the incidence of total adverse events was 8.2 % in the exposed group, mainly manifested as stomach discomfort, diarrhea, and hepatocyte damage.Conclusion1. In the exposed group, the two-year rate of invasive disease-free survival increased by 6.2 % compared with the non-exposed group(P＞0.05). 2. According to K–M survival analysis, TNBC patients with age ≤35 years and regional lymph node metastasis to N1 may be potential beneficiaries of “TCM formula”. 3. “TCM Formula” is safe and tolerable to most patients.     

基于VOSviewer的2019新型冠状病毒病中医临床诊疗可视化分析＊

目的 通过对公开发表在网络和数据库的有关中医药治疗2019新型冠状病毒肺炎（corona virus disease 2019，COVID-19）的文献进行方、药、证的可视化分析，客观全面的对COVID-19的中医药治疗进行探讨，为现代中医临床诊疗提供参考。方法 本文选用运用文献计量学方法和VOSviewer可视化软件对纳入文献中的用药情况进行数据拆分、整理和分析。结果 本研究高质量数据的主要期刊来源是核心期刊《中医杂志》；新冠临床用方以解表清热剂、开窍补益剂、辟秽祛湿剂为主；临床用药以解表药、清热解毒药、化湿祛痰药以及补益药为主；临床治病思路以六经辨证、三焦辨证和卫气营血辨证理论为指导；临床常见证型为湿、热、寒、毒相关证型；重视新冠前期预防以及后期恢复调养；治疗过程用药考究，注重养阴与祛邪并进。结论 新冠的中医临床诊治考病全面，并注重养阴与祛邪并进，可为官方制定治疗方案提供参考。     

中医药对淋巴管新生与回流功能的作用研究进展＊

淋巴管作为循环系统的重要组成部分之一，具有调节机体体液稳态，协助免疫监视和肠道脂质吸收等重要作用。淋巴管新生是机体生理和病理过程中维持脉管系统结构和功能正常的重要手段，淋巴管新生调控对于防治肿瘤、心血管等诸多疾病有着潜在的临床转化意义；淋巴回流功能则与关节炎症等疾病发病机制关系密切。在循环系统中，相较于中医药调控血管相关疾病的发病机制已取得很大进展，近年来对于淋巴管的研究则明显相对滞后。本文从中医药作用于淋巴管新生及回流功能角度对这一领域的研究进展作一综述，以期为临床上中医药治疗相关疾病提供新的思路与方法。     

紧密型医联体模式下全科医学科建设探索

目的 探讨紧密型医连体模式下全科医学科的定位。 方法 通过对比分析国内全科医学科的发展和深圳市5家区属医院全科医学科的实际运行情况，探索紧密型医联体模式下全科医学科在组织架构、功能定位和学科发展方面的建设。 结果 我国全科医学科的发展主要依赖学科联盟，通过教学师资输出与师资培养在临床基地和实践基地间建立联系。紧密医联体模式下全科医学科发展可借用行政手段强力推进，有利于分级诊疗。2016年深圳市社康机构基本医疗服务人次占全市公立医疗机构门急诊总诊疗量的42.66%。选择在社区首诊的医保参保人数量863万，占全市参保人总数的70%。深圳市区属医院全科医学科在组织架构上多采用双重管理模式，即在业务上归属医务科等职能部门管理，行政上归属社区健康管理中心管理。全科医学科在功能定位上侧重于全科教学，着重于全科医学人才培养，为基层输送合格的全科医生。全科门诊是全科医生的主要带教场所，全科住院部适合收治多病共存、未分化疾病和教学患者，有利于全科医生对典型患者的系统学习。 结论 紧密型医联体模式有利于分级诊疗推进，该模式下全科医学科组织架构可采用双重管理，其功能定位为全科教学，其学科发展方向为多病共存患者照顾。      

健脾温肾软坚解毒方、康艾注射液联合低剂量化疗治疗老年脾肾两虚型晚期非小细胞肺癌的临床研究

目的观察健脾温肾软坚解毒方、康艾注射液联合低剂量化疗对老年脾肾两虚型晚期非小细胞肺癌患者瘤灶、免疫功能及无进展生存期的影响。方法将80例老年脾肾两虚型晚期非小细胞肺癌患者随机分为治疗组和对照组,每组40例。对照组予常规剂量化疗,治疗组予健脾温肾软坚解毒方、康艾注射液联合低剂量化疗。化疗2个周期后,观察两组患者瘤灶、免疫功能的变化情况,随访患者的无进展生存期。结果①试验期间,对照组脱落2例,试验组无脱落,最终完成试验者78例,其中治疗组40例,对照组38例。②两组实体瘤疗效比较,差异无统计学意义(P0.05)。③化疗1个周期与化疗前组内比较,两组血清NK、CD3~+、CD4~+、CD8~+水平差异无统计学意义(P0.05);化疗2个周期与化疗前组内比较,治疗组血清CD8~+水平升高(P0.05),对照组血清NK、CD3~+、CD4~+水平降低(P0.05)。化疗1个周期后组间比较,治疗组血清CD3~+、CD4~+水平高于对照组(P0.05);化疗2个周期后组间比较,治疗组血清NK、CD3~+、CD4~+水平高于对照组(P0.05)。④两组患者中位无进展生存时间均为4.5个月,差异无统计学意义(P0.05)。结论健脾温肾软坚解毒方、康艾注射液联合低剂量化疗能有效控制老年肺肾两虚型晚期非小细胞肺癌患者的瘤灶变化,并有利于稳定血清NK、CD3~+和CD4~+水平,保护患者的免疫功能。     

基于“双心理论”探讨新型冠状病毒肺炎合并心血管疾病的病理机制及中西医结合治疗策略

基于"双心理论"探讨新型冠状病毒肺炎(简称"新冠肺炎")合并心血管疾病的病理机制及中西医结合治疗策略。认为焦虑、抑郁情绪可加重新冠肺炎合并心血管疾病患者的病情,其机制可能与肾素-血管紧张素系统激活有关。临床可采用语言疏导、中式保健操、五行音乐等物理疗法以及西药等干预措施;同时结合中医药疗法,分为肝气郁滞证、心脾两虚证、心脉瘀阻证和痰火扰心证进行辨证论治。